Last reviewed · How we verify
AZD9833 with ribociclib — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
AZD9833 with ribociclib (AZD9833 with ribociclib) — AstraZeneca.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| AZD9833 with ribociclib TARGET | AZD9833 with ribociclib | AstraZeneca | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- AZD9833 with ribociclib CI watch — RSS
- AZD9833 with ribociclib CI watch — Atom
- AZD9833 with ribociclib CI watch — JSON
- AZD9833 with ribociclib alone — RSS
Cite this brief
Drug Landscape (2026). AZD9833 with ribociclib — Competitive Intelligence Brief. https://druglandscape.com/ci/azd9833-with-ribociclib. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing